Jiangsu Jiangfeng Pharmaceutical Technology

Jiangsu Jiangfeng Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Changzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on metabolic diseases, oncology, and autoimmune disorders, with a leading program targeting hyperuricemia and gout. Its pipeline is anchored by JF-001, a potent URAT1 inhibitor designed to provide superior efficacy and safety compared to existing treatments. Jiangfeng Pharmaceutical leverages its internal R&D capabilities to advance a diverse portfolio of candidates through various stages of clinical and preclinical development. The company aims to address significant unmet medical needs in the global and domestic Chinese markets through precision medicine and optimized drug design.